CoreCap Advisors’s Haemonetics HAE Stock Holding History

CoreCap Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$211	Hold	2	–	–	﹤0.01%	2949
2026 Q2	$150	Buy	+2	New	+$128	﹤0.01%	3040
2025 Q2	–	Sell	-3	Closed	-$191	–	2954
2025 Q1	$191	Buy	+3	New	+$204	﹤0.01%	2991
2024 Q4	–	Sell	-547	Closed	-$44K	–	2910
2024 Q3	$44K	Buy	+547	New	+$44.2K	﹤0.01%	1241
2024 Q2	–	Sell	-783	Closed	-$66.8K	–	2009
2024 Q1	$66.8K	Buy	+783	New	+$61.4K	﹤0.01%	1000
2022 Q4	$70.2K	Buy	+892	New	+$71.7K	0.01%	864
2022 Q1	–	Sell	-4	Closed	-$1K	–	1166
2021 Q4	$1K	Buy	+4	New	+$244	﹤0.01%	2133

Other funds holding HAE

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Isthmus Partners Madison, Wisconsin $1.04B AUM 19.97% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.36B AUM 20.86% 1-Year Est. Return

Cardinal Capital Management Inc (North Carolina) Raleigh, North Carolina $861M AUM 27.19% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $762M AUM 14.92% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return

CoreCap Advisors's HAE Position: Q3 2026 in Review

CoreCap Advisors held its Haemonetics (HAE) position steady in Q3 2026 at 2 shares worth $211. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

CoreCap Advisors first reported a position in HAE in Q4 2021 and has held it in 7 quarters since. The position peaked at $70.2K in Q4 2022. 40 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

CoreCap Advisors held 2 shares of Haemonetics worth $211 as of Q3 2026.
CoreCap Advisors left its Haemonetics share count unchanged in Q3 2026.
Haemonetics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2949 holding.
CoreCap Advisors first reported a position in Haemonetics in Q4 2021 and has held it in 7 quarters since.
CoreCap Advisors's Haemonetics position peaked at $70.2K in Q4 2022.
40 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.